Speech-Language Pathologists in Mississippi State, MS Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Janie Cirlot-new, M.S., CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 326 Hardy Road, Mississippi State, MS 39762 Phone: 662-325-1028 Fax: 662-325-0896 |
Lori L Arinder, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 326 Hardy Road, Mississippi State, MS 39762 Phone: 662-325-1028 |
Mrs. Cynthia Diane Cockerham Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 326 Hardy Road, Mississippi State, MS 39762 Phone: 662-325-0876 |
Janette Hreish, MS. CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 326 Hardy Road, Mississippi State, MS 39762 Phone: 662-325-1028 |
News Archive
Home dialysis can benefit patients who receive urgent in-center hemodialysis
Researchers have studied whether patients who start urgent and unplanned dialysis in clinics experience a survival benefit when they switch to home dialysis.
The Gambia introduces pneumococcal immunisation programme
The Gambia, Minister of Health Dr. Mariatou Jallow administered the first dose of the pneumococcal vaccine to Gambian children at a rural clinic outside Banjul today. Joined by the Gambia's Vice President, Mrs. Isatou Njie-Saidy, Dr. Jallow and hundreds of Gambian citizens celebrated this historic event, which marks the first step in the rollout of the Gambia's national pneumococcal immunisation programme.
NYSE publicly traded industry selects EPGL's advanced technologies for development
EP Global Communications, Inc., makes the following announcement: In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products.
Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
› Verified 1 days ago